Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating ...
In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.
NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...
COPENHAGEN, Denmark I September 16, 2024 I Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing ...
As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...
Bangkok Dusit Medical, Medikaloka Hermina and more in the latest Market Talks covering the Health Care sector.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's ...
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback